Alumis’ (ALMS) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Alumis (NASDAQ:ALMS) in a research report sent to investors on Thursday,Benzinga reports.

Other equities research analysts have also issued reports about the stock. Oppenheimer assumed coverage on shares of Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective (down from $19.00) on shares of Alumis in a report on Thursday. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $26.00.

Alumis Price Performance

Alumis stock opened at $3.75 on Thursday. The firm has a 50 day moving average of $5.69 and a 200 day moving average of $8.56. Alumis has a 12-month low of $3.18 and a 12-month high of $13.53.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC bought a new position in shares of Alumis during the 3rd quarter valued at approximately $3,266,000. State Street Corp bought a new position in shares of Alumis during the 3rd quarter valued at approximately $866,000. Charles Schwab Investment Management Inc. bought a new position in shares of Alumis during the 3rd quarter valued at approximately $1,160,000. Stifel Financial Corp bought a new position in shares of Alumis during the 3rd quarter valued at approximately $931,000. Finally, Barclays PLC bought a new position in shares of Alumis during the 3rd quarter valued at approximately $197,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.